yts169 4  (Bio X Cell)

Journal: The American Journal of Pathology

Article Title: Inhibiting the Secreted RGDKGE Collagen Peptide Selectively Controls CD8 + T-Cell Migration on Denatured Collagen-IV and Enhances Their Accumulation in Tumors

doi: 10.1016/j.ajpath.2025.09.008

Figure Lengend Snippet: CD8 + T cells control tumor growth following targeting the RGDKGE collagen peptide. C57BL/6 mice were treated intraperitoneally with function-blocking anti–CD8α-depleting antibody (BP0061) or non-specific control antibodies. A: Example of flow cytometry analysis for CD8 + T cells from spleens of mice treated with non-specific control antibody (Ab Cont) or anti–CD8α-depleting antibody (Anti-CD8). B: Quantification of CD8 + T cells from spleens of mice treated with non-specific control antibody (Ab Cont) or anti–CD8α-depleting antibody (Anti-CD8). Data represent CD8 + T cells from four mice per group. C: Example of flow cytometry analysis for CD4 + T cells from spleens of mice treated with non-specific control antibody (Ab Cont) or anti–CD8α-depleting antibody (Anti-CD8). D: Quantification of CD4 + T cells from spleens of mice treated with either non-specific control antibody (Ab Cont) or anti–CD8α-depleting antibody (Anti-CD8). Data represent CD4 + T cells from four mice per group. E: Examples of CD8 + T cells (red) in B16F10 tumor section from either non-specific control antibody (Ab Cont) or anti–CD8α-depleting antibody (Anti-CD8) treated mice. F: Quantification of the mean CD8 + T-cell count from four different tumors from each treatment group using five to seven ×200 microscopic fields from each tumor. Data represent CD8 + T-cell counts from four different tumors from each treatment group. G: Quantification of B16F10 tumor size from control antibody-depleted (Ab Cont) or CD8-depleted (Anti-CD8) mice over 14 days. Data points represent tumor volume from four mice per condition. H: Quantification of B16F10 tumor size from control antibody-depleted mice treated with non-specific control antibody (Ab Cont) or anti-RGDKGE antibody [monoclonal antibody (Mab) XL313] over 14 days. Data points represent tumor volume from eight mice per condition. I: Quantification of B16F10 tumor size from CD8-depleted mice treated with non-specific control antibody (Ab Cont) or anti-RGDKGE antibody (Mab XL313) over 14 days. Data points represent tumor volume from seven to eight mice per condition. Data are given as means ± SEM ( B , D , and F – I ). ∗ P < 0.05, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Scale bars = 50 μm ( E ). SSC, side scatter.

Article Snippet: Mab XL313, functional blocking anti-CD8α (BP0061) used for depletion, and non-specific control antibodies were acquired from Bio X-Cell (Lebanon, NH).

Techniques: Control, Blocking Assay, Flow Cytometry, Cell Characterization

Journal: Frontiers in Immunology

Article Title: Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis

doi: 10.3389/fimmu.2025.1748085

Figure Lengend Snippet: Neutrophil depletion affects CD8 + T-cell abundance in the brain of JEV-S3 and JEV-S1-infected mice. (A) Cell populations from the blood, spleen, and brain at the onset of symptoms in neutrophil-depleted JEV-S1 infected mice (n=6 mice in each group) were assessed by flow cytometry. CD11b, Ly6C, Ly6G, CD3, CD4, and CD8 T-cells were identified and described in the Materials and Methods section. (B) Cell population from the brain was assessed at the onset of symptoms in neutrophil-depleted JEV-S3-infected mice. The top (A, B) and bottom (C, D) panels represent % T cells and count for the same experiments. Error bars are defined as SEM. P -values are calculated using an unpaired Student’s t-test; *P<0.05; **P<0.01, ***P<0.001.

Article Snippet: Anti-mouse CD8a (clone 53.6-7, #BP0004-1), anti-rat Kappa immunoglobulin (clone MAR18.5, # BE0122), and corresponding were purchased from Bio X Cell, USA, and injected intraperitoneally following the schemes and dosage that are presented in the figures or legends.

Techniques: Infection, Flow Cytometry

Journal: Frontiers in Immunology

Article Title: Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis

doi: 10.3389/fimmu.2025.1748085

Figure Lengend Snippet: Flow cytometric analysis of immune infiltrating cells in JEV-S3-infected-treated brain. (A) Schematic diagram representing experimental plans. C57BL/6 (n=4 mice in each time-point) were treated intraperitoneally with AMD3100 at 4mg/Kg/mouse before 12 h of JEV-S3 infection. After every 12 h, the antagonist was given till day 5, and mice were harvested on days 3 and 5. (B) Comparison of cell surface markers CD11b, Ly6G, Ly6C, CD3, CD4, and CD8 on blood (B, D) and brain (C, E) cells from JEV-S3 and treated-AMD3100 infected mice. Data in all bar graphs are presented as SEM. Statistical significance was determined using a one-way ANOVA test: *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Anti-mouse CD8a (clone 53.6-7, #BP0004-1), anti-rat Kappa immunoglobulin (clone MAR18.5, # BE0122), and corresponding were purchased from Bio X Cell, USA, and injected intraperitoneally following the schemes and dosage that are presented in the figures or legends.

Techniques: Infection, Comparison

Journal: Frontiers in Immunology

Article Title: Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis

doi: 10.3389/fimmu.2025.1748085

Figure Lengend Snippet: Immune cell abundance and infiltration in blood and brain, respectively, in JEV-S1-infected-treated mice. (A) Schematic diagram representing experimental plans. C57BL/6 (n=4 mice in each time-point) were treated intraperitoneally with AMD3100 at 4mg/Kg/mouse before 12 h of JEV-S1 infection, and after every 12 h, the antagonist was given till day 11. Mice were harvested on days 9 and 12. (B) Quantification of cell surface markers CD11b, Ly6G, Ly6C, CD3, CD4, and CD8 on blood (B, D) and brain (C, E) cells from JEV-S1 and treated-AMD3100 infected mice. All data are expressed as SEM; statistical significance was determined using a one-way ANOVA test: *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Anti-mouse CD8a (clone 53.6-7, #BP0004-1), anti-rat Kappa immunoglobulin (clone MAR18.5, # BE0122), and corresponding were purchased from Bio X Cell, USA, and injected intraperitoneally following the schemes and dosage that are presented in the figures or legends.

Techniques: Infection

Journal: Frontiers in Immunology

Article Title: Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis

doi: 10.3389/fimmu.2025.1748085

Figure Lengend Snippet: CXCR4 expression pattern in neutrophil-depleted mice in blood and brain. (A) Schematic representation of experimental plans: IP injection of anti-Ly6G and Isotype 300 µg/mice (n=6 in each group) were given before 48 h of JEV-S1 infection, and antibodies were given as depicted in the schematic figure. (B, C) The contour plots represent the percentage of CD4+ and CD8+T cells at day 9 from blood and brain (upper panel). The count of CXCR4 + cells was determined in CD8 + and CD4 + T cells; quantification of CXCR4 + cells on CD8 + and CD4 + T cells in blood and brain is shown in the lower panel. (D, E) Intracellular and surface staining of CD8 T-cells from Blood and spleen for Granzyme B, at day 9 post-infection, respectively. P - values were calculated using two-tailed unpaired Student’s t-test; *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Anti-mouse CD8a (clone 53.6-7, #BP0004-1), anti-rat Kappa immunoglobulin (clone MAR18.5, # BE0122), and corresponding were purchased from Bio X Cell, USA, and injected intraperitoneally following the schemes and dosage that are presented in the figures or legends.

Techniques: Expressing, Injection, Infection, Staining, Two Tailed Test

Journal: Frontiers in Immunology

Article Title: Neutrophil depletion at the early stage of Japanese encephalitis virus infection affects CD8+ T cell infiltration into the mouse brain and causes severe encephalitis

doi: 10.3389/fimmu.2025.1748085

Figure Lengend Snippet: Contribution of CD8 + T-cells to control of JEV infection. (A) Schematic representation of experimental plans for CD8 depletion. IP injection of anti-mouse CD8α and Isotype (150 µg/mouse) was given before 48 h of JEV-S1 infection, and antibodies were given as depicted in the schematic figure. (B) Contour plots represent the percentage of CD4 and CD8+ cells. Lymphocyte cell counts (n=4 in each group) in peripheral blood at day 0 and day 6, depicted as a bar graph. P -values are calculated using an unpaired Student’s t-test; ***P<0.001. (C) Kaplan-Meier survival curve of isotype and anti-CD8α-JEV-S1 infected mice (n=7 in each group). (D) The change in the body weight of CD8 + T-cells depleted of JEV-S1 and isotype-infected mice. (E) The Clinical Score is shown in the CD8 + T-cells-depleted group and isotype-infected mice. The color represents a score (0–5) related to the clinical symptoms; ‘0’ represents no symptoms, and 5 represents the most severe symptoms. (F) The expression levels of NS3 and GAPDH were detected in the infected mice brains by immunoblotting.

Article Snippet: Anti-mouse CD8a (clone 53.6-7, #BP0004-1), anti-rat Kappa immunoglobulin (clone MAR18.5, # BE0122), and corresponding were purchased from Bio X Cell, USA, and injected intraperitoneally following the schemes and dosage that are presented in the figures or legends.

Techniques: Control, Infection, Injection, Expressing, Western Blot

Journal: Cancer Research

Article Title: PRMT3 Drives IDO1-Dependent Radioresistance and Immunosuppression by Promoting Kynurenine Metabolism in Non–Small Cell Lung Cancer

doi: 10.1158/0008-5472.CAN-24-4162

Figure Lengend Snippet: PRMT3 influences NSCLC by modulating the tumor-immune microenvironment. A, A subcutaneous xenograft model was constructed in immunodeficient nude mice. Compared with immune-competent mice, PRMT3 overexpression did not exhibit the same tumor-promoting effects in the nude mice ( n = 7). RT, radiotherapy. B, Pan-cancer analysis from TCGA revealed that PRMT3 affects the tumor-immune microenvironment. C, High PRMT3 expression in patients with NSCLC was associated with reduced CD8 + T-cell infiltration. D, IF confirmed PRMT3’s inhibitory effect on CD8 + T cells. Scale bar, 20 μm. E and F, Flow cytometry analysis of mouse tumors was performed ( n = 5). G, ELISA demonstrated that PRMT3’s effect on Kyn metabolism could be rescued by 1-MT ( n = 3). H–J, Coculturing CD8 + T cells extracted from mouse spleen with LLC cells ( H ) showed that PRMT3-overexpressing tumor cells upregulated Kyn metabolism ( I ) and reduced granzyme B expression in CD8 + T cells ( J ). K and L, qRT-PCR analysis of CYP1A1, CYP1B1 ( K ), and PD-1 ( L ) expression in CD8 + T cells ( n = 3). M, PRMT3 inhibitor enhanced the efficacy of radiotherapy combined with immunotherapy in NSCLC ( n = 7). aPD-L1, anti–PD-L1; D, day. N, IHC was used to stain relevant markers in the NSCLC patient cohort and assess their correlation. Data represent the mean ± SD. Differences were tested using one-way ANOVA test ( A and E–M ), Wilcoxon rank-sum test ( C ), and unpaired two-sided Student t test ( N ). The correlation was determined using Spearman correlation test ( B and C ). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Article Snippet: InVivoPlus anti-mouse CD8α (Bio X Cell, BP0061), 350 μg/mouse/time, intraperitoneal injection, once every 4 days.

Techniques: Construct, Over Expression, Expressing, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Quantitative RT-PCR, Staining

Journal: Exploration

Article Title: A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors

doi: 10.1002/EXP.20240396

Figure Lengend Snippet: STEPT‐mediated prevention of recurrence and combat distal “cold” tumor in mice model of breast cancer. (A–G) STEPT‐mediated prevention of recurrence in a model of breast cancer. (A–C) Illustration of experimental protocols for STEPT; FCM, Flow cytometry. (B) G5 indicated the control group. (D) Representative bioluminescence images of tumor and (E) 4T1‐luc tumor growth curves of 4T1‐luc tumor‐bearing mice after the indicated treatment in (A) and (B); n = 10 biologically independent mice. (F) Illustration of memory CD8 + T cells analysis. (G) Quantitative analysis of effector memory (EM) T cells and central memory (CM) T cells in the spleen at day 93 after the indicated treatment; n = 10 biologically independent samples. (H–N) Usefulness of STEPT treatment to combat distal “cold” tumor models in mice. (H,I) Illustration of experimental protocols for distal cold tumor therapy in 4T1‐luc tumor‐bearing mice. (I) showed the grouping arrangement. (J) Representative bioluminescence images of 4T1‐luc tumor‐bearing mice; n = 10 biologically independent mice. (K) CFUs of EcN‐pfo in tumors at different time points after the indicated treatment; n = 10 biologically independent mice. The graphs were discontinued after day 7 because of tumor regression in the G‐STEPT group. (L) Growth rates of proximal (hot) and distal (cold) 4T1‐luc tumors after the indicated treatment. Plot of tumor growth rate (mm 3 /day) of treated compared to untreated tumors for each mouse. Dotted line indicates slope = 1, points represent means, error bars represent S.E.M.; n = 10 biologically independent mice. (M) Illustration of memory CD8 + T cells analysis by flow cytometry at day 20. (N) Quantitative analysis of the EM T cells and CM T cells in tumors at day 20 after the indicated treatment; n = 10 biologically independent samples. (O) Clickable hydrogel and programmable bacteria for spatiotemporally targeted therapy against solid tumors. Data in (E,G,K,L,N) expressed as the mean ± SEM. P values determined by unpaired two‐tailed Student's t ‐test (G,N) or two‐way ANOVA with Bonferroni post‐hoc test (E,K).

Article Snippet: To consume CD8 + or CD4 + T cells, 250 mg InVivoMAb anti‐mouse CD8α (BP0004‐1, BioXCell), anti‐mouse CD4α (BP0003‐1, BioXCell) or isotype control (BP0089, BioXCell) were intraperitoneally injected on days −1, 6, 15, and 24 of the courses of treatment.

Techniques: Flow Cytometry, Control, Bacteria, Two Tailed Test